Interpharm (AMEX:IPA)
Historical Stock Chart
From Jun 2019 to Jun 2024
Interpharm Holdings, Inc. (Amex: IPA)(“Holdings”),
a manufacturer and distributor of generic pharmaceutical products,
announced today that it received a notice from the American Stock
Exchange Continued Listing Department that it is out of compliance with
exchange rules.
On April 10, 2008, Interpharm Holdings, Inc. (the “Company”)
received notice from the American Stock Exchange (“AMEX”)
that the Company is not in compliance with the following continuing
listing standards contained in the AMEX Company Guide:
1. Section 1003(a)(i) because of stockholders equity less than
$2,000,000 and losses from continuing operations and net losses in two
out of its three most recent fiscal years;
2. Section 1003(a)(ii) because of stockholders equity of less than
$4,000,000 and losses from continuing operations and net losses in three
out of its four most recent fiscal years; and
3. Section 1003(a)(iv) because of sustained losses.
In response to the AMEX letter, the Company plans to submit a plan of
operations demonstrating how it will regain compliance with AMEX
continuing listing standards.
About Interpharm Holdings, Inc.
Interpharm currently develops, manufactures and distributes generic
prescription strength and over-the-counter pharmaceutical products.
Interpharm will continue to focus on growing organically through
internal product development and leveraging its strength in efficient
and cost effective manufacturing. In addition, Interpharm will also
continue to seek consummation of mutually beneficial strategic alliances
and collaborations.
FORWARD-LOOKING STATEMENTS
Statements made in this news release, contain forward-looking statements
concerning Interpharm's business and products involving risks and
uncertainties that could cause actual results to differ materially from
those reflected in the forward-looking statements. The actual results
may differ materially depending on a number of risk factors including,
but not limited to, the following: general economic and business
conditions, development, shipment, market acceptance, and additional
competition from existing and new competitors, changes in technology,
and various other factors beyond Interpharm's control. Other risks
inherent in Interpharm's business are set forth in its filings with the
SEC.
All information in this release is as of April 16, 2008. Interpharm
undertakes no duty to update any forward-looking statements to conform
the release to actual results or changes in its circumstances or
expectations after the date of this release.